S.C. Medisprof S.R.L

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Gastric and oesophageal cancer1 trial
• Kidney cancer1 trial
• Melanoma1 trial

Phase

• Phase 35 trials

Status

• Active, not recruiting2 trials
• Completed2 trials
• Recruiting1 trial

Lead sponsor

• Amgen1 trial
• Daiichi Sankyo1 trial
• EMD Serono Research & Development Institute, Inc.1 trial
• Pfizer1 trial
• Pierre Fabre Medicament1 trial

Running trials

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

  NCT06430866· Phase 3· Amgen· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Pierre Fabre Medicament· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer1 recruiting

Closed trials

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Pfizer· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source